Abstract: TH-PO0469
Efficacy and Safety of Nefecon in the Treatment of IgAN: A Multicenter Real-World Retrospective Study
Session Information
- Glomerular Diseases: Clinical, Outcomes, and Therapeutics Research - IgAN
October 22, 2026 | Location: Exhibit Hall A, Convention Center
Abstract Time: 10:00 AM - 12:00 PM
Category: Glomerular Diseases
- 1402 Glomerular Diseases: Clinical, Outcomes, and Therapeutics
Authors
- Lu, Fang, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China
- Yuan, Yanggang, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China
Background
Nefecon has shown efficacy against immunoglobulin A nephropathy (IgAN) in randomized controlled trials. However, real-world evidence for its effectiveness is limited. This multicenter retrospective study aimed to evaluate the efficacy and safety of Nefecon in Chinese patients with IgAN.
Methods
A total of 403 Nefecon-treated patients with IgAN were enrolled in a 9-month longitudinal cohort study. Proteinuria remission at 9 months was considered as the primary outcome.
Results
At the 9-month follow-up, the proteinuria overall remission rate was 71% (40% CR, which was defined as proteinuria < 0.5 g/d. 31% PR, which was defined as proteinuria < 1 g/d or at least a 50% decline from the baseline). Median proteinuria decreased from 1300 mg/d to 713 mg/d, while the eGFR remained stable with an 8.2% increase. Among patients with proteinuria < 1 g/d, the overall remission rate was 77%, higher than the 64% observed in those with proteinuria ≥ 1 g/d. The overall remission rate in initially treated patients was 83.33%, higher than the 66.24% in retreated patients. Multivariable analysis identified treatment status, baseline proteinuria, and T score as independent predictors of proteinuria remission. Nefecon was well-tolerated, with only mild-to-moderate adverse events reported, and no serious adverse events occurred.
Conclusion
In this multicenter real-world cohort, Nefecon significantly reduced proteinuria and stabilized renal function, demonstrating a favorable safety profile. Early treatment initiation was key determinants of treatment response.